Tectonic Therapeutic (NASDAQ:TECX) CFO Daniel Lochner Purchases 4,617 Shares

Tectonic Therapeutic (NASDAQ:TECX) CFO Daniel Lochner purchased 4,617 shares of the business’s stock in a transaction that occurred on Wednesday, February 5th. The stock was acquired at an average cost of $54.14 per share, with a total value of $249,964.38. Following the completion of the acquisition, the chief financial officer now directly owns 4,617 shares of the company’s stock, valued at $249,964.38. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Tectonic Therapeutic Trading Down 14.4 %

Shares of NASDAQ TECX opened at $36.45 on Friday. The firm has a market capitalization of $537.64 million, a PE ratio of -6.19 and a beta of 2.62. The firm’s 50-day moving average is $45.25 and its 200-day moving average is $34.39. Tectonic Therapeutic has a 1 year low of $13.80 and a 1 year high of $61.07.

Tectonic Therapeutic (NASDAQ:TECX) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.36). As a group, equities research analysts anticipate that Tectonic Therapeutic will post -8.31 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in TECX. Nordwand Advisors LLC bought a new stake in Tectonic Therapeutic in the third quarter valued at about $45,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Tectonic Therapeutic during the 4th quarter worth about $144,000. Charles Schwab Investment Management Inc. bought a new stake in shares of Tectonic Therapeutic in the 4th quarter valued at about $218,000. Raymond James Financial Inc. acquired a new stake in shares of Tectonic Therapeutic in the 4th quarter valued at approximately $228,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in Tectonic Therapeutic during the 3rd quarter worth approximately $233,000. Institutional investors and hedge funds own 62.63% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on TECX. Raymond James started coverage on shares of Tectonic Therapeutic in a research report on Wednesday, November 20th. They issued an “outperform” rating and a $65.00 price objective for the company. Leerink Partners raised their price target on shares of Tectonic Therapeutic from $49.00 to $69.00 and gave the company an “outperform” rating in a report on Monday, November 11th. Finally, Wells Fargo & Company upped their price objective on Tectonic Therapeutic from $79.00 to $112.00 and gave the stock an “overweight” rating in a report on Friday, January 31st. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $80.50.

Tectonic Therapeutic Company Profile

Avrobio, Inc is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc is based in MA, United States.